Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harrow Health Inc (HROW)
NASDAQ:HROW
Holding HROW?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.02Last Year’s EPS
-$0.26Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: -33.94%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic product launches, particularly with VEVYE and the retina pivot strategy. However, inventory issues with VEVYE and seasonal impacts on revenue were noted as challenges.Company Guidance
During the third quarter of 2024, Harrow reported record revenue of $49.3 million, marking a 44% increase from the prior year and a small increase over the previous quarter. The company's key product, VEVYE, experienced a 55% increase in prescription volume compared to the second quarter, despite facing an inventory shortage. VEVYE's refill rate is impressive, with over 90% of patients refilling their prescriptions. IHEEZO saw a 15% sequential rise in unit demand from the second quarter and an 82% reorder rate. The company made a strategic decision to focus on the retina specialist community, which is expected to bolster IHEEZO's performance. Additionally, TRIESENCE was relaunched in October, with positive initial responses, particularly regarding reimbursement. Harrow's commercial team expanded the number of covered territories for VEVYE from 51 to 61, contributing to its growth trajectory.Record Revenue Growth
Harrow reported record revenue of $49.3 million, a 44% increase over the prior year quarter, indicating strong growth.
VEVYE Prescription Success
VEVYE prescription volume increased by 55% in the third quarter compared to the second quarter, with a refill rate of over 90%.
Operational Improvements and New Product Launches
Implemented the 'retina pivot' strategy, focusing on the retina specialist community, which is already showing benefits. TRIESENCE was successfully relaunched in October.
---
HROW Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HROW Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $51.80 | $42.86 | -17.26% |
| Aug 07, 2024 | $21.98 | $33.92 | +54.32% |
| May 13, 2024 | $12.07 | $16.24 | +34.55% |
| Mar 19, 2024 | $10.65 | $10.52 | -1.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Harrow Health Inc (HROW) report earnings?
Harrow Health Inc (HROW) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Harrow Health Inc (HROW) earnings time?
Harrow Health Inc (HROW) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HROW EPS forecast?
HROW EPS forecast for the fiscal quarter 2024 (Q4) is $0.02.
---
